Peripheral Neuritis Treatment Market Analysis

Application (Diabetic, Chemotherapy-Induced, Idiopathic)

The peripheral neuritis treatment market is segmented and analyzed for demand and supply by application into diabetic, chemotherapy-induced, idiopathic, and others. Among these, the diabetic segment is anticipated to garner the largest revenue by 2036 on the back of a rising diabetic population in the world as well as a rising number of people opting for peripheral neuritis treatment. For instance, a report published in 2019 stated that diabetic peripheral neuropathy is estimated to affect around 50% of adults with diabetes during their lifetime.

Our in-depth analysis of the global peripheral neuritis treatment market includes the following segments:

By Drug Class	Anti-Depressants Tricyclic Selective Serotonin/ Norepinephrine Reuptake Inhibitors Serotonin Reuptake Inhibitors Anticonvulsants Local Anesthesia Analgesics NSAID Opioid Steroids Others
By Application	Anti-Depressants Tricyclic Selective Serotonin/ Norepinephrine Reuptake Inhibitors Serotonin Reuptake Inhibitors Anticonvulsants Local Anesthesia Analgesics NSAID Opioid Steroids Others
By Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies Drug Stores

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of peripheral neuritis treatment is estimated at USD 1.93 Billion.

The peripheral neuritis treatment market size was valued at USD 1.87 Billion in 2023 and is likely to cross USD 3.03 Billion by the end of 2036, registering more than 3.8% CAGR during the forecast period i.e., between 2024-2036. The rising chronic diseases globally, and the large aging population are some of the major factors anticipated to drive the growth of the market.

North America industry is expected to account for majority revenue share by 2036, backed by presence of a large pool of diabetic patients and a burgeoning aging population in the region.

Eli Lilly and Company, Abbott, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GSK Group of Companies, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, RxFunction, Inc., Cipla Limited

Peripheral Neuritis Treatment Market Analysis